KERYX BIOPHARMACEUTICALS INC Litigation

Jun 21, 2021

Ruling on Appeal - Closed

Oct 4, 2019

On Appeal

Apr 30, 2019

Motion for Class Certification

The plaintiffs have asked the court to approve the lawsuit to proceed as a class action on behalf of a group of investors. The judge will decide whether the case meets the requirements for class certification and which investors and claims may be included.

Apr 1, 2019

Voluntary Dismissal

The plaintiff in this action has chosen not to proceed with the case. Once a case is voluntary dismissed, the courts will usually close the case and no further action will be taken.

Jul 19, 2018

Motion to Dismiss Denied

The court has denied the defendants' request to dismiss the lawsuit. The case can now move forward to the next stage of litigation.

Oct 2, 2017

Motion to Dismiss

After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.

Feb 27, 2017

First Amended Complaint

A new complaint has been filed on behalf of certain investors in KERYX BIOPHARMACEUTICALS INC. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.

Dec 28, 2016

Appointment of Lead Plaintiff

The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.

Aug 26, 2016

First Filed Complaint

A securities fraud class action complaint has been filed on behalf of certain investors in KERYX BIOPHARMACEUTICALS INC.